Latest Axoltis News & Updates

See the latest news and media coverage for Axoltis. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Axoltis

Biopharmaceutical company developing neurological disease treatments

axoltis.com
Headquarters
Lyon, France
Company type
Private company
Number of employees
15–50
Industry
Pharmaceuticals

Last updated

Latest news about Axoltis

In short: Axoltis reported NX210c’s ALS trial signals, although the Phase 2 study missed its primary endpoint.

Company announcements

Axoltis

Axoltis presents preliminary Phase 2 results for NX210c in ALS

The SEALS trial showed NX210c has a good safety profile and suggests efficacy signals in ALS patients at week 6.

Unlock all announcements with a

Media coverage

Endpoints News

Axoltis ALS Drug Phase 2 Study Fails Primary Endpoint

French biotech Axoltis reports a Phase 2 failure for NX210c in amyotrophic lateral sclerosis, missing the primary endpoint but showing secondary signals of slower disease progression.

The Pharma Letter

Axoltis Pharma raises 18 million euros

Axoltis Pharma, a French biotech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announced the closing of an 18 million euros ($20.9...

Les Échos

Charcot's Disease: Axoltis mobilizes 18 million euros for its peptide

The phase II study of NX210c, the code name of Axoltis' candidate drug, should validate a repair of the blood-brain barrier. (DR) By Stephane Frachet...

Unlock all articles with a

Never miss news about Axoltis

Track Axoltis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.